Published in Health Business Week, May 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Biovail.
Report 1: Biovail Corporation (NYSE, TSX: BVF) and Depomed, Inc. (NASDAQ: DEPO) announced today that the companies have entered into an agreement that provides Biovail with access to Depomed's proprietary AcuForm (TM) drug-delivery technology for the development of up to two Biovail products.
Under the terms of the agreement, Depomed has granted Biovail Laboratories International SRL, a subsidiary of Biovail, an option to license Depomed's AcuForm (TM) technology to develop...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.